Nintedanib

Excerpt

Nintedanib is a small molecule tyrosine kinase inhibitor that binds to growth factor receptors, inhibiting the proliferation of fibroblasts. This action reduces ongoing fibrotic processes and delays the progression to long-lasting damage. Nintedanib is indicated for treating idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and progressive phenotype interstitial lung disease. This activity reviews the indications, contraindications, and adverse events associated with nintedanib therapy. The activity also covers the administration, pharmacokinetics, and relevant interactions of nintedanib, providing knowledge crucial for tailoring treatment to individual patient needs.